GreenLight Biosciences Holdings (NASDAQ: GRNA) is -83.36% lower on its value in year-to-date trading and has touched a low of $0.18 and a high of $8.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The GRNA stock was last observed hovering at around $0.18 in the last trading session, with the day’s gains setting it 0.02% off its average median price target of $2.30 for the next 12 months. It is also 95.0% off the consensus price target high of $4.00 offered by 2 analysts, but current levels are 66.67% higher than the price target low of $0.60 for the same period.
Currently trading at $0.20, the stock is -14.41% and -43.91% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.78 million and changing 11.03% at the moment leaves the stock -85.27% off its SMA200. GRNA registered -97.34% loss for a year compared to 6-month loss of -83.64%. The firm has a 50-day simple moving average (SMA 50) of $4.34 and a 200-day simple moving average (SMA200) of -$0.31.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The stock witnessed a -38.44% gain in the last 1 month and extending the period to 3 months gives it a -65.39%, and is 1.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.66% over the week and 10.11% over the month.
GreenLight Biosciences Holdings (GRNA) has around 262 employees, a market worth around $30.22M and $10.30M in sales. Distance from 52-week low is 11.03% and -97.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-218.30%).
GreenLight Biosciences Holdings (GRNA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for GreenLight Biosciences Holdings (GRNA) is a “Overweight”. 2 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
GreenLight Biosciences Holdings is expected to release its quarterly report on 08/14/2023.The EPS is expected to shrink by -38.60% this year
GreenLight Biosciences Holdings (GRNA) Top Institutional Holders
The shares outstanding are 151.61M, and float is at 86.52M with Short Float at 3.81%.
GreenLight Biosciences Holdings (GRNA) Insider Activity
A total of 0 insider transactions have happened at GreenLight Biosciences Holdings (GRNA) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Builders Vision, LLC, the company’s 10% Owner. SEC filings show that Builders Vision, LLC bought 6,505,102 shares of the company’s common stock on Aug 11 at a price of $3.92 per share for a total of $25.5 million. Following the purchase, the insider now owns 22.35 million shares.
GreenLight Biosciences Holdings disclosed in a document filed with the SEC on Aug 11 that Walker Matthew Allen (Director) bought a total of 6,377,551 shares of the company’s common stock. The trade occurred on Aug 11 and was made at $3.92 per share for $25.0 million. Following the transaction, the insider now directly holds 22.22 million shares of the GRNA stock.
Still, SEC filings show that on Aug 11, Morningside Venture Investment (10% Owner) acquired 3,061,224 shares at an average price of $3.92 for $12.0 million. The insider now directly holds 15,919,155 shares of GreenLight Biosciences Holdings (GRNA).
